Arrowhead Pharmaceuticals, Inc. (ARWR)
86.74
-0.37
(-0.42%)
USD |
NASDAQ |
Aug 24, 16:00
86.74
0.00 (0.00%)
After-Hours: 20:00
Arrowhead Pharmaceuticals Enterprise Value : 12.07B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 12.07B |
| August 20, 2026 | 12.12B |
| August 19, 2026 | 12.39B |
| August 18, 2026 | 12.18B |
| August 17, 2026 | 12.29B |
| August 14, 2026 | 12.00B |
| August 13, 2026 | 11.85B |
| August 12, 2026 | 12.09B |
| August 11, 2026 | 12.37B |
| August 10, 2026 | 12.24B |
| August 07, 2026 | 12.15B |
| August 06, 2026 | 11.89B |
| August 05, 2026 | 12.04B |
| August 04, 2026 | 12.42B |
| August 03, 2026 | 11.91B |
| July 31, 2026 | 11.72B |
| July 30, 2026 | 12.10B |
| July 29, 2026 | 11.94B |
| July 28, 2026 | 11.88B |
| July 27, 2026 | 11.85B |
| July 24, 2026 | 11.86B |
| July 23, 2026 | 12.02B |
| July 22, 2026 | 12.29B |
| July 21, 2026 | 10.29B |
| July 20, 2026 | 9.887B |
| Date | Value |
|---|---|
| July 17, 2026 | 10.26B |
| July 16, 2026 | 9.848B |
| July 15, 2026 | 9.911B |
| July 14, 2026 | 9.924B |
| July 13, 2026 | 10.23B |
| July 10, 2026 | 10.56B |
| July 09, 2026 | 11.63B |
| July 08, 2026 | 11.88B |
| July 07, 2026 | 12.05B |
| July 06, 2026 | 11.99B |
| July 02, 2026 | 11.63B |
| July 01, 2026 | 11.13B |
| June 30, 2026 | 11.28B |
| June 29, 2026 | 10.89B |
| June 26, 2026 | 10.66B |
| June 25, 2026 | 10.72B |
| June 24, 2026 | 10.79B |
| June 23, 2026 | 10.81B |
| June 22, 2026 | 11.10B |
| June 18, 2026 | 11.08B |
| June 17, 2026 | 10.97B |
| June 16, 2026 | 10.33B |
| June 15, 2026 | 10.42B |
| June 12, 2026 | 10.05B |
| June 11, 2026 | 10.03B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sarepta Therapeutics, Inc. | 2.242B |
| Intellia Therapeutics, Inc. | 1.433B |
| Denali Therapeutics, Inc. | 3.308B |
| Twist Bioscience Corp. | 9.051B |
| Revolution Medicines, Inc. | 42.13B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -178.92M |
| Revenue (Quarterly) | 75.25M |
| Total Expenses (Quarterly) | 269.53M |
| EPS Diluted (Quarterly) | -1.355 |
| Gross Profit Margin (Quarterly) | 91.15% |
| Profit Margin (Quarterly) | -237.8% |
| Earnings Yield | -2.59% |
| Normalized Earnings Yield | -2.586 |